We examined the relationship between CLDN18 expression levels and MSI (Microsatellite Instability) and TMB (Tumor Mutation Burden) to determine if CLDN18 could serve as a predictive marker for the response to immunotherapy across various cancer types. This evidence concerns the gene CLDN18 and neoplasm.